Last reviewed 2026-04-19 · How we verify

Routine use of P-CAB on DAPT

Samsung Medical Center · Phase 2 active Small molecule

Routine use of P-CAB on DAPT is a Small molecule drug developed by Samsung Medical Center. It is currently in Phase 2 development.

At a glance

Generic name	Routine use of P-CAB on DAPT
Sponsor	Samsung Medical Center
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Routine use of P-CAB on DAPT CI brief — competitive landscape report
Routine use of P-CAB on DAPT updates RSS · CI watch RSS
Samsung Medical Center portfolio CI

Frequently asked questions about Routine use of P-CAB on DAPT

What is Routine use of P-CAB on DAPT?

Routine use of P-CAB on DAPT is a Small molecule drug developed by Samsung Medical Center.

Who makes Routine use of P-CAB on DAPT?

Routine use of P-CAB on DAPT is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

What development phase is Routine use of P-CAB on DAPT in?

Routine use of P-CAB on DAPT is in Phase 2.

Manufacturer: Samsung Medical Center — full pipeline
Compare: Routine use of P-CAB on DAPT vs similar drugs
Pricing: Routine use of P-CAB on DAPT cost, discount & access